The Life Science Innovation Northwest 2022 assembly was dwell and in individual this week in Seattle. A whole bunch of researchers and entrepreneurs mingled on the metropolis’s conference heart, attending panels on every little thing from the science of cell remedy to the state of biotech funding within the present bear market.
The assembly launched with a dialog between former Juno Therapeutics executives Hans Bishop and Steve Harr, who each went on to co-found Sana Biotechnology. The Seattle firm went public final yr in the biggest IPO ever for a preclinical biotech firm. GeekWire coated the chat and spoke with Bishop and Harr in an interview afterwards.
The assembly is placed on every year by the commerce group Life Science Washington, which has a brand new CEO, Marc Cummings. I interviewed Cummings on stage on the assembly. He talked about the right way to strengthen the trade and bolster the workforce, and the priorities of his group for the longer term.
Learn on for these headlines and extra of the week’s life science information within the Pacific Northwest.
Extra Pacific Northwest life science information beneath:
- A single dose of the vaccine for human papillomavirus works simply in addition to the usual three-dose routine, opening the door to larger entry worldwide, in response to a study led by UW world well being professor Ruanne Barnabas.
- The dog aging project, which profiles how canines age and checks whether or not the drug Rapamycin can lengthen lifespan, was featured within the Seattle Instances. The funders of the College of Washington venture embody a consortium of tech entrepreneurs.
- Seattle’s Lumen Bioscience accomplished a section 1 examine of its capsules for C. difficile infections, produced with inexperienced algae. The algae are engineered to make three antibody-like proteins that neutralize a C. difficile toxin, together with an enzyme that degrades the cell wall of the microbe. The trial information confirmed that the remedy made it to the proper place within the intestine and that the therapeutic proteins have been secure within the physique, in response to a press release. The corporate additionally lately printed its preclinical information in a preprint and its method in Nature Biotechnology. The U.S. Meals and Drug Administration has green-lit a phase 2 trial.